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1372Objective: Transcatheter aortic valve implantation has been used to treat high-risk patients with bioprosthetic
valve degeneration (valve-in-valve).We report our experience with transcatheter aortic valve implantation in the
treatment of degenerated biologic aortic valve prostheses and discuss factors that can influence the outcome.
Methods: From February 2009 to October 2011, 278 patients underwent transcatheter aortic valve implantation,
of whom 23 underwent a valve-in-valve procedure with the Edwards Sapien valve to treat a failing bioprostheses
in the aortic position. Eight of these valves were stentless bioprostheses. Thirteen patients had valve failure re-
sulting predominantly from stenosis, and the remaining resulting from regurgitation.
Results:Mean age was 76.9 14.4 years. The mean logistic EuroSCORE was 31.8% 20.3% and the Society
of Thoracic Surgeons score was 7.6%  5.4%. All patients were New York Heart Association class III or IV.
The majority of the operations (21/23) were performed via the transapical route. Procedural success was 100%,
although 1 patient with a degenerated homograft needed immediate placement of a second valve because of low
placement of the first. The reduction in the mean gradient was 31.2  17.06 mm Hg to 9.13  4.9 mm Hg. In
those patients with predominant aortic regurgitation (9/23), reduction in aortic regurgitation was achieved in all.
The median length of stay was 11.7 days (range, 3-44 days). In-hospital and/or 30-day mortality was 0%.
Conclusions: Valve-in-valve is a safe and feasible alternative to treat high-risk patients with failing aortic bio-
prostheses. The early results are excellent, with improvement seen in hemodynamics. (J Thorac Cardiovasc Surg
2012;144:1372-80)Transcatheter aortic valve implantation (TAVI) has emerged
as a viable treatmentmodality for patients with severe native
aortic valve stenosis and multiple comorbidities that would
typically preclude them from surgery.1-3 The ‘‘on-label’’
indication for TAVI using the Edwards Sapien device
(Edwards Lifesciences, Irvine, Calif) is native calcific
aortic stenosis in a tricuspid aortic valve in absence of any
other prosthesis in the heart.2,3 Novel applications of
TAVI, such as use in aortic stenosis in a bicuspid valve,4
TAVI in the presence of mitral prosthesis,5 and valve-in-
valve (VIV),6-16 have gathered momentum as a result of
clinical need. Although small in number when compared
with the number of TAVI implants, the number of VIV
procedures has increased rapidly in 2011. In addition toe Department of Cardiothoracic Surgery and Cardiology, Guys and St.
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The Journal of Thoracic and Cardiovascular Surthe case reports, a few case series from single institutions
and collaborative series’ from multiple institutions have
demonstrated feasibility and acceptable early results in
selected patients.6-16 The majority of the experience in
VIV has been in the treatment of failing stented
bioprosthetic aortic valves and, to date, there are only
isolated reports of the use of TAVI in the setting of
a failing stentless bioprostheses.9,10,13
The concept and initial results have been encouraging.
VIV procedures are currently undertaken if the conven-
tional redo operation is deemed high risk. We present our
VIV experience in 23 consecutive patients using the Ed-
wards transcatheter valve (Sapien and Sapien XT). We
also discuss the technical considerations and current limita-
tions of the VIV procedure.METHODS
Patient Characteristics
Between February 2009 and October 2011 we performed 23 VIV TAVI
procedures for aortic bioprosthetic degeneration using the Edwards Sapien
and SapienXT valve.Mean patient agewas 76.9 14.4 years (range, 29-92
years). The male-to-female ratio was 1.3:1. The mode of presentation was
either severe aortic valve regurgitation (n ¼ 9) or stenosis (n ¼ 14). The
mean logistic EuroSCORE (LES) was 31.8%  20.3% and the mean
Society of Thoracic Surgeons score was 7.6%  5.4%. Patients were dis-
cussed in a multidisciplinary team meeting (MDT) comprised of 2 cardiac
surgeons, 2 intervention cardiologists, 1 noninvasive cardiologist, and 1gery c December 2012
Abbreviations and Acronyms
BAV ¼ balloon aortic valvuloplasty
CT ¼ computed tomographic
LES ¼ logistics Euroscore
MDT ¼ multidisciplinary team meeting
TA ¼ transapical
TAVI ¼ transcatheter aortic valve implantation
TEE ¼ transesophageal echocardiogram
TF ¼ transfemoral
VIV ¼ valve-in-valve
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Dcardiac anesthetist. Patients were also discussed with a respiratory physi-
cian and a geriatrician when indicated. These patients were thought to be
at high risk for conventional open aortic valve replacement and hence
were accepted for TAVI. Patients’ baseline characteristics are listed in
Table 1. Of these 23 patients, 15 patients had a stented bioprosthesis and
8 patients had a stentless aortic bioprosthesis. The mean length of time
from the previous aortic valve procedure for stented valves and stentless
valves was 9.4 3.86 years (range, 4-19 years) and 14 6.21 years, respec-
tively. Details of various degenerated bioprostheses are listed in Table 2.
Preoperative Investigations
Three patients had undergone at least 3 open surgical procedures. Other
than routine investigations, the preoperative diagnostic workup included
a transthoracic echocardiogram, coronary and peripheral angiography,
a noncontrast computed tomographic (CT) scan of the aorta, a respiratory
function test, and a carotidDoppler examination. In addition, a preoperative
transesophageal echocardiogram (TEE) was carried out in all patients with
a stentless aortic bioprosthesis to determine the exact aortic annular diam-
eter. Infective endocarditis was ruled out in all patients, which is especially
important when the mode of valve failure is regurgitation. Prior operative
notes were consulted when available to obtain details of the type of valve
implanted, the valve size, and the surgical technique used.
Operative Technique
The procedures were all performed in a cardiac catheterization labora-
tory by a combined team of cardiac surgeons, cardiologists, and anesthe-
siologists. A perfusionist was also always present with an assembled
heart–lung machine. The approach for TAVI was either transfemoral
(TF) or transapical (TA). The choice of the approach was dependent on
the type of bioprosthesis in situ and the size of the femoral arteries.
We preferred the TA approach in all cases of stented bioprostheses and
when the size of the femoral arteries was not suitable for TF access in
cases of stentless bioprostheses. The techniques for both approaches
have been described in detail elsewhere.17,18 For the TA approach,
Ascendra 1 and Ascendra 2 delivery systems were used with Sapien
and Sapien XT valves, respectively. For the TF approach, the Novoflex
delivery system was used with the Sapien XT valve. All procedures
were performed under fluoroscopic and TEE guidance.
In the case of stented bioprostheses, the size of the Sapien or Sapien XT
valve to be implanted was determined according to the internal diameter of
the degenerated prosthesis provided by the manufacturer. Valve design and
fluoroscopic appearance of the degenerated bioprosthesis were studied for
correct and secure placement of the Sapien valve. We have published else-
where19 the guidance on the design, fluoroscopic appearance, and dimen-
sions of all bioprosthetic valves as well as the ideal position of a TAVI
device during the VIV procedure. A size 23-mm Sapien valve was used
if the internal diameter of the valve stent was<22 mm, a 26-mm prosthesisThe Journal of Thoracic and Carwas used for an internal diameter of 23 to 25 mm, and a 29-mm prosthesis
was used for an internal diameter of 26 to 28 mm.
In case of a stentless bioprosthesis, the size of the new valve to be
implanted was determined according to the internal diameter of the aortic
annulus as in a native aortic valve measured by preoperative chest CT scan
and intraoperative TEE. Internal dimensions available from the valve
literature and operative records in cases of homografts were consulted.
The final decision, however, was based predominantly on the intraopera-
tive TEE.
Simultaneous fluoroscopic, angiographic, and TEE imaging were used
routinely to guide the precise level for valve deployment. Balloon aortic
valvuloplasty (BAV) of the degenerated valve prior to insertion of the pros-
thesis was not undertaken. Also, slow and gradual implantation was per-
formed during a short phase of ventricular rapid pacing (Figure 1).
It can be difficult to visualize the level of the annulus in stentless valves
because they are not as calcified as native aortic valves, the mode of presen-
tation is most likely to be regurgitation, and, unlike stented valves, they
have no radiologic markers.9,10 We have used 2 procedural modifications
to achieve correct implantation in these cases, which are discussed
subsequently.
Postimplant Assessment
Aortography and TEE assessment were used to determine the correct
placement and function of the Sapien valve and patency of the coronary ar-
teries. TEE assessment was used to identify and grade paravalvular leak
(mild, moderate, and severe).
Discharge and Follow-up
Patients were monitored closely postoperatively per the requirements of
our onsite registry, which includes patient interviews, clinical examination,
and follow-up echocardiography. All patients were discharged on dual anti-
platelet therapy for the first 3 months and a single agent thereafter unless
contraindicated clinically.
Statistical Analyses
Continuous variables are described as mean  standard deviation; di-
chotomous or nominal variables are described as numbers and percentages.
Statistical analyses were performed using SPSS (version 17.0 forWindows,
SPSS Inc, Chicago, Ill).RESULTS
Intraoperative
The procedural success rate was 100%. One patient with
a degenerated homograft had an immediate second VIV im-
plant after low placement of the first valve resulting from
difficulty in visualizing the level of the annulus. One patient
had a right ventricular perforation from 1 of the transvenous
pacing wires used during the procedure. This was diagnosed
immediately as a pericardial effusion on the TEE and was
repaired without the use of cardiopulmonary bypass. In 15
patients, a 23-mm Sapien valve was implanted (13 stented
valves and 2 stentless valves), in 6 patients a 26-mm valve
was implanted (2 stented valves and 4 stentless valves), and
in 2 patients a 29-mm valve was implanted (both stented
valves). The sizes of in situ bioprostheses and the Sapien
valve used are listed in Tables 2 and 3. The mean
procedure time was 89  28.5 minutes (range, 44-135
minutes). The mean fluoroscopy time was 11.4  4.9
minutes (range, 5.5-18 minutes). The mean volume ofdiovascular Surgery c Volume 144, Number 6 1373
TABLE 1. Baseline patient characteristics
Parameter Value (±SD) Range
No. of patients 23 —
Male, n 13 —
Age, y 79.6 43-92
Time since valve insertion, y 14.1  6.4 6-27
Logistic EuroSCORE,% 31.6  15.3 4-58.2
STS score,% 6.3  3.8 3.2-18.9
LVEF,% 48.0  12.4 23-62
Previous CABG or PCI 9 —
Previous stroke 2 —
eGFR<60 14 —
COPD 6 —
PVD 1 —
Regurgitation as mode of original valve failure, n 9 —
NYHA class III or IV, n 23 —
SD, Standard deviation, STS, Society of Thoracic Surgeons; LVEF, left ventricular
ejection fraction; CABG, coronary artery bypass grafting; PCI, percutaneous coro-
nary intervention; eGFR, estimated glomerular filtration rate; COPD, chronic ob-
structive pulmonary disease; PVD, peripheral vascular disease; NYHA, New York
Heart Association.
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Dcontrast medium used during the procedure was 52 mL
(range, 0-150 mL). More contrast was used when treating
stentless valves. After valve implantation, the mean peak
gradient and mean gradient decreased from 54.54  29.2
TABLE 2. Bioprosthetic valve characteristics: Baseline and after VIV
Patient Valve type Valve size ID
Sapien valve
size used
Valve
age, y
M
Stented
1 Perimount 25 24 26 9
2 CE 21 19 23 19
3 CE 21 19 23 12
4 Soprano 22 21.7 23 11
5 Mitraflow 23 19 23 6
6* Mitraflow 19 15.4 23 8
7 Perimount 25 24 26 12
8 Perimount 21 20 23 9
9 Perimount 29 28 29 9
10* CE 19 17 23 12
11* Mosaic 21 18.5 23 4
12 Mitraflow 23 19 23 4
13 Perimount 23 22 23 11
14* Mitraflow 21 17.3 23 5
15 Perimount 29 28 29 10
Stentless
16 Homograft 23 23 26 15
17 St. Jude Toronto SPV 23 23 23 17
18 Homograft 22 22 26 13
19 Homograft 21 21 23 27
20 Sorin Pericarbon 23 23 23 7
21 Homograft 23 23 26 14
22 St. Jude Toronto SPV 23 26 10
23 Homograft 20 23 9
ID, Internal diameter; MG, mean gradient; AR, aortic regurgitation; CE, Carpentier Edwar
value-in-value.
1374 The Journal of Thoracic and Cardiovascular Surmm Hg to 16.5  9.8 mm Hg and 31.2  17.06 mm Hg
to 9.13  4.9 mm Hg, respectively. Five patients had mild
paravalvular aortic regurgitation postimplantation whereas
the other 18 patients had no regurgitation.Postoperative
During the early postoperative course, therewere 3 signif-
icant complications: 1 patient required reoperation for ve-
nous bleeding from the epicardium after having the
procedure via the TAapproach (4.35%), 1 patient developed
transient right-sided weakness on postoperative day 1 that
later resolved completely (4.35%) and 4 patients developed
acute kidney injury necessitating temporary hemodialysis
(17.39%). There were no postoperative myocardial infarc-
tions, no indications for postoperative pacemaker insertion,
and nowound complications. Themedian intensive care unit
length of stay was 1 day (range, 0.5-13 days) and median
length of stay was 11 days (range, 3-44 days). There was
no in-hospital and/or 30-day mortality. All patients were
NewYorkHeart Association class II at the time of discharge.Follow-up Data
There were no early or late valve reinterventions or open
conversions. The mean follow-up was 8.1 months (range,ode of
failure Route Preoperative MG Postimplant MG Residual AR
S TA 33 5 Grade 1
R TA 11 3 None
R TA 9 4 None
S TA 54 17 None
R TA 5 12 None
S TA 30 13 None
S TA 26 9 None
S TA 66 5 None
S TA 43 8 Grade 1
S TA 22 8 None
S TA 46 4 None
R TA 17 11 None
S TA 39 7 None
S TA 31 20 None
S TA 36 11 Grade 1
R TA 9 16 None
R TA 33 10 None
S TA 72 20 None
R TF 24 14 Grade 1
R TA 31 8 None
R TF 23 5 None
R TA 9 9 Grade 1
S TA 41 8 None
ds porcine valve; S, stenosis; R, regurgitation; TA, transapical; TF, transfemoral; VIV,
gery c December 2012
FIGURE 1. Valve-in-valve for a failed Carpentier Edwards (CE) porcine valve. A, Photograph of CE porcine valve showing relationship between sewing
ring (a), radio-opaque stent (b), and leaflets (c). B, Beginning of the procedure showing the ease with which one can obtain a good view for the procedure
without use of contrast. C, Positioning of the Sapien valve within the CE porcine prosthesis. The aim is to deploy 20% below the sewing ring, which is
achieved by matching the lower margin of the Sapien valve to the lower margin of the frame of CE Prosthesis. D, Fully deployed Sapien valve in an ideal
position
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period. One death was the result of rupture of a large ab-
dominal aortic aneurysm on day 46. The patient had under-
gone a VIV procedure successfully and was awaiting a stent
procedure for the abdominal aortic aneurysm. The second
death was a result of respiratory failure on day 63, which
was precipitated by pneumonia. The third death was the re-
sult of a massive gastric bleed on day 105. This patient was
on single-agent antiplatelet therapy.DISCUSSION
During the past decade, there has been an increase in
valve procedures, especially aortic valve replacement.
Newer generation bioprostheses are reported to last longer,
and hence the age bar for implantation of a bioprosthesis has
been lowered.20 It is conceivable that the majority of these
patients are going to outlive the bioprosthesis and will
present for redo aortic valve replacement in the future. Re-
finements in operative technique and postoperativemanage-
ment have led to low morbidity and mortality rates.21 The
operative mortality for an elective redo aortic valve surgery
is reported to range from 2% to 7%, but this percentage canTABLE 3. Stentless valve types and their implantation options
Valve name (manufacturer) Implantation technique
Toronto SPV (St. Jude Medical) Subcoronary
Toronto Root (St. Jude Medical) Full root, inclusion root
Freestyle (Medtronic) Full root, inclusion root,
subcoronary
Prima Plus (Edwards LifeSciences) Full root, inclusion root,
subcoronary
CryoLife-O’Brien (CryoLife) Subcoronary
Elan (AorTech) Subcoronary
Shelhigh Superstentless (Shelhigh) Subcoronary
Shelhigh Bioconduit (Shelhigh) Full root
Biocor PSB/SJM (St. Jude Medical) Subcoronary
Pericarbon Freedom (Sorin) Subcoronary
3F Aortic Bioprosthesis (3F Therapeutics) Subcoronary
The Journal of Thoracic and Carincrease to more than 30% in high-risk patients.21 Further-
more, redo operations are also associated with increasing
morbidity and prolonged recovery.21 For this subset of pa-
tients, VIV TAVI represents a less invasive alternative to
conventional redo surgery.
In 2007,Wenaweser and colleagues6 reported the first suc-
cessful application of VIV TAVI using a 26-mm CoreValve
(Medtronic Ltd, Minn) in the treatment of a degenerated bio-
prosthesis (23-mm Mitraflow) in the aortic position. Since
then, multiple authors have demonstrated that VIV TAVI is
technically feasible and safe, with excellent early results
and low mortality using either the Sapien valve or the Core-
Valve.7-16 Immediate hemodynamic improvement and early
results have been encouraging in this cohort of patients. The
first multicenter experience using the Sapien valve was
reported by Webb and associates,7 who reported 24 high-
risk patients with an LES of 30.4%  9.7% and a Society
of Thoracic Surgeons score of 10.0% 5.2%. Implantation
was successful in all but 1 patient, in whom the valve embol-
ized into the distal aorta. There were no procedural deaths,
and 30-day mortality was 4.2%. Gotzmann and coworkers8
reported the first series using the self-expanding CoreValve.
The average LES in their 5 patients was>30%. Procedural
success was 100% with mild perivalvular/paravalvular
leak in 2 of 5 patients and a reduction in the peak gradient
from 67.6 19.3 mmHg to 21.2 11.4 mmHg. Pacemaker
requirements have been reported to be minimal and were
none in our series.7,8,13-15 Experience in VIV for stentless
bioprostheses is comparatively less.13 Traditionally, the use
of TAVI has been contraindicated in patients with aortic re-
gurgitation, which is the primary mode of failure of stentless
valves. However, the inherent bulk of the stentless valve and
the sutures used for its implantation can provide anchoring
for the new stented valve. Nevertheless, VIV in a stentless
valve is a more challenging procedure. Choice of valve
used is operator dependent. Of the 17 patients reported in
the literature and our 8 patients, 18 patients were treated
with the Sapien valve and 7 with the CoreValve.13diovascular Surgery c Volume 144, Number 6 1375
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on patient selection, understanding the design of the degen-
erated bioprosthesis, anticipation of complications, and pro-
cedural planning. It is important that the team is
experienced in TAVI before undertaking a VIV procedure.
We discuss here some important aspects in planning and
performing a VIV case.
Patient Selection
In our center, we consider the VIV procedure only when
the patient is considered high risk for a conventional redo
procedure. Each patient is discussed at our MDT.22 Certain
technical and design characteristics of the bioprosthetic
valve in situ are studied before accepting the patient for
a VIV procedure. We use the Edwards Sapien device, which
currently is only available in 3 sizes: 23 mm, 26 mm, and 29
mm. The annulus range in which it is used to treat a native
aortic stenosis is 18 to 27mm. Thus, using this device, a sur-
geon can only perform VIV in bioprosthesis valves with in-
ternal diameters ranging from 18 to 27 mm. Similar size
limitations apply for the CoreValve.13 If used in valves
with a larger internal diameter, it can result in valve embo-
lization.13 If used for a smaller diameter bioprosthesis, it
would lead to underexpansion of the Sapien valve, which
may interfere with its short-term and long-term hemody-
namic performance and a high residual gradient.13,23
Pasic and associates,11 in one of the earliest VIV series,
felt that the VIV procedure in these patients should only
be undertaken as a last resort. Although many reports
have since emerged demonstrating successful results in
smaller valves, including 1 patient in our series with stent
internal diameter<18 mm, we concur with them and accept
these patients only when the reoperation risks are prohibi-
tive. One also must be aware that the internal diameter of
the bioprosthetic valve provided by the manufacturer is of
the ‘‘stent’’ without leaflets. Thus, in reality, the actual in-
ternal diameter is smaller than provided.19
Route for VIV
In the initial reports of VIV, the TA route was preferred
because it allowed better control and fine adjustment during
valve placement.11 Furthermore, crossing of a stented bio-
prosthesis was much easier via the TA route and is indepen-
dent of the size of the peripheral vessels. However, in
centers in which both Sapien and CoreValve devices are
used routinely, the choice seems to depend on the access
route—CoreValve for a TF approach and Sapien for a TA
approach.13 With the current modifications to the TF deliv-
ery systems for the Sapien valve (ie, Novoflex delivery sys-
tem), which include a nosecone at the tip and minimal
movement of the device during valve deployment, the TF
route is being used increasingly for VIV procedures for
a stented bioprostheses.14 The choice, however, depends en-
tirely on the comfort of the team and its experience with1376 The Journal of Thoracic and Cardiovascular Sura particular delivery system. We have used the TA route
for stented valves, in patients with stentless valves when
their peripheral arteries were not suitable for TF, and
when the aortic root anatomy was challenging (eg, a hori-
zontal aorta).
Valve Design and Characteristics
It is of paramount importance to familiarize oneself with
the design, fluoroscopic appearance, and implantation tech-
nique of the degenerated bioprosthetic valve for a successful
outcome and to minimize complications such as malposi-
tioning, valve embolization, and coronary obstruction.13,24
Stented Valves
Internal diameter. From the standpoint of VIV implanta-
tion, it is the internal diameter of the failed valve that is
most relevant. We have published a complete chart of inter-
nal diameter measurements of the majority of commercially
available bioprosthetic valves.19 It should be kept in mind
that the disease process affecting the implanted valve can
have varying effects on the internal diameter, including cal-
cification and/or thickening of the tissue leaflets and pannus
in growth. Pannus and calcification can reduce the internal
diameter of the stent significantly. Hence, CT scanning
and TEE are an important adjunct to available internal diam-
eter in choosing the correct size of the TAVI valve by iden-
tifying presence of calcification and pannus, respectively.
This fact is highlighted in the series published by Webb
and colleagues,7 in which 2 patients had a degenerated
25-mm Carpentier-Edwards Perimount valve (internal stent
diameter, 24 mm). Both were treated successfully but 1
was treated with a 23-mm Sapien valve most likely because
of pannus ingrowth and the other with a 26-mm Sapien.
Fluoroscopic appearance. We have recently published
a guide to fluoroscopic appearances of various surgically
implanted bioprosthetic valves.19 Because the sewing ring
of the bioprosthetic valve, which is sutured to the native aor-
tic annulus, provides the most reliable rigid anchor to hold
the TAVI valve in place, it is important to know the relation-
ship between the fluoroscopic markers and the location of
the sewing ring (Figure 1).
Design. In certain valves (eg, the Sorin Mitraflow and the
St. Jude Trifecta), the leaflets are sutured outside the stent
posts. After a VIV procedure, the leaflets are pushed farther
out and this can result in coronary obstruction, especially in
patients with smaller aortic root dimensions.24
Stentless Valves
During the past 2 decades, there have been a number of
stentless valves that have been commercially available
worldwide and each has specific recommendations regard-
ing implantation options (Table 3).
Internal diameter. When performing TAVI in the setting
of a stentless valve, we have erred on choosing a largergery c December 2012
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neither heavily calcified like native aortic valves nor have
a frame like a stented bioprosthesis. Hence, a 23-mm Sapien
valve was used if the internal diameter of the annulus was
<21mm, and a 26-mmwas used for an internal diameter be-
tween 21 mm and 24 mm. In the case of a borderline annu-
lus, such as 21 mm, a larger prosthesis (26-mm Sapien) was
preferred if the leaflets were not bulky and circumferential
annular calcification was minimal. We feel that this degree
of oversize is essential to achieve secure anchoring of the
device and is a key factor in contributing to the technical
success of the procedure in those patients with primary aor-
tic regurgitation. Self-expanding TAVI devices such as the
CoreValve may have an advantage in this situation and
are preferred by a few operators.13
Fluoroscopic appearance. None of the commercially
available stentless valves are radio-opaque (Figure 2),
which makes the procedure challenging, especially when
the mode of failure is regurgitation.
Design and implantation technique. Unlike stented
valves, stentless valves can be implanted using 1 of 3 tech-
niques detailed in the Table 3. It is essential to know how the
initial valve was implanted. In certain valves, such as Cry-
oLife-O’Brien (CryoLife) and Pericarbon Freedom (Sorin),
the suture lines are in proximity to the native coronary ostia,
and VIV can result in coronary obstruction.
VIV Positioning and Deployment: Stented Valves
Stented bioprostheses provide good fluoroscopic land-
marks for a VIV procedure. When the Sapien valve is
used, the aim should be to place the valve at least 20% be-
low the sewing ring of the bioprosthesis (Figure 1); and for
the CoreValve, at least 6 mm below the sewing ring,7,12,19
which results in secure anchoring of the TAVI device.
Details of VIV positioning for various types of
bioprostheses have been reported elsewhere.7,12,19
VIV Positioning and Deployment: Stentless Valves
In contrast to stented bioprostheses, implantation of the
Sapien valve within a stentless valve poses a different setFIGURE 2. Valve-in-valve in a stentless valve. A, Fluoroscopy showing minim
during deployment of the Sapien device. Pigtail catheter is pulled back halfway t
is placed in the left main to provide a landmark for correct deployment of Sap
The Journal of Thoracic and Carof technical challenges. Unlike native aortic valves, the
failed stentless valves usually present with aortic regurgita-
tion and are not heavily calcified. They also lack radio-
opaque markers to facilitate positioning and a rigid frame
to provide anchoring. In addition, the design and techniques
of implantation of certain stentless valves may bring the
coronary ostia in closer proximity to the annulus. To maxi-
mize precise deployment, we perform routinely a slow and
gradual inflation of the prosthesis during a single short
phase of rapid ventricular pacing as described by Pasic
and colleagues. 11
We have also used 2 procedural modifications. In the first,
in the presence of free regurgitation (n ¼ 4), a guidewire
was placed in the left main ostium to provide a distal land-
mark during deployment because it was impossible to deter-
mine the correct level of the aortic annulus (Figure 2, A). In
the second, when the regurgitation was less or the valve was
stenotic, we placed a pigtail catheter at the base of the sinus
during implantation and injected contrast during gradual in-
flation of the device, which provided good delineation of the
aortic annulus. The pigtail was withdrawn just before com-
plete expansion of the Sapien valve (Figure 2, B). TEE is an
important adjunct in these cases and can aid in correct
placement of the Sapien valve.
Role of BAV
The majority of cases of VIVare now performed without
a BAV.13 Degenerated bioprosthetic leaflets can be bulky
and friable, and BAV can result in embolization of the de-
bris and leaflet tears, resulting in severe aortic regurgitation.
However, one can use BAV to determine risk of coronary
occlusion after VIV and to locate the level of the annulus
in the case of stentless valves and stented valves without
radio-opaque markers (Figure 3).
Hemodynamic Results
Uneven deployment. A TAVI valve performs best when
deployed circularly throughout its length. Thus, uneven ex-
pansion can result in poor hemodynamic performance. The
internal diameter of the existing bioprosthesis at the level ofal calcification in a failed stentless valve (red arrow). B, Contrast injection
hrough the deployment. C, In patients with severe regurgitation, a guidewire
ien valve (black arrow).
diovascular Surgery c Volume 144, Number 6 1377
FIGURE 3. Role of balloon aortic valvuloplasty (BAV) in valve-in-valve. A, BAV showing the ‘‘waist’’ in the balloon delineating the level of the annulus
(red arrow). B, BAVwith a 20-mm balloon and simultaneous aortogram showing left main occlusion (white arrow) in a case of failed Freedom solo stentless
valve. The right coronary artery was unobstructed (black arrow).
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sion because the stent posts can be splayed outward.
Uneven deployment can result in a conical or dumbbell-
shaped deployment when using the Sapien valve
(Figure 4). This problem will only be minimized when
a wider range of sizes of TAVI valves becomes available
to ensure an exact match.
Residual gradient. As a result of the placement of a valve
inside another valve, there is a concern about significant re-
sidual gradients resulting from a ‘‘Russian nested doll’’ ef-
fect. Postprocedural gradients are in the range of 10 to 22
mm Hg in most series.7,11,13,14 Higher residual gradients
are observed in smaller bioprostheses.13 Eggerbrecht and
associates25 reported a trend of favorable hemodynamics
when using the CoreValve in small bioprostheses (21
mm) compared with the Sapien valve, but the numbers
were too small to draw definite conclusions. The main con-
cern is in patients with a bioprosthesis with an internal di-
ameter<19 mm. In our series, 4 patients with an internal
diameter of 19 underwent VIV with a 23-mm Sapien
valve. Two patients had higher residual mean gradients
but continue to have excellent symptomatic improvement.FIGURE 4. Uneven expanssion of the Sapienvalve after a VIV procedure.
A, Final shape is conical or ‘‘top hat’’ when deployed<20% below the
sewing ring. B, Final shape is dumbell-shaped when deployed>20%
below the sewing ring.
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and hence VIV may be offered in such cases when there
is no surgical option.7,11,12,14
Residual regurgitation. Residual regurgitation can be the
result of a paravalvular/perivalvular leak or a transvalvular
leak. A transvalvular leak can be a result of underexpansion
or an uneven expansion of the TAVI device.13 In our series,
6 patients had residual grade 1 leaks, all of which were para-
valvular. Residual regurgitation resulting from a paravalvu-
lar leak is a significant problem when TAVI is used to treat
the native valve, but most published series reporting experi-
ence with VIV have observed minimal residual regurgita-
tion, similar to our experience.7,11,13,14 A degenerated
bioprosthesis provides a circular annulus and less bulky
leaflets, which allow an even expansion and better
opposition of a TAVI device, thus resulting in a less
degree of paravalvular leak when compared with a native
stenotic aortic valve.Future Direction
VIV implantation has been performed successfully in de-
generated bioprostheses in the mitral, tricuspid, and pulmo-
nary positions.7,15,16 Work is in progress from various
groups to provide clinicians with robust bench data on this
indication, and there is a possibility of trials for Conformite
Europeene (CE) mark in the near future. Availability of
more sizes of TAVI devices and specific TAVI devices for
VIV will facilitate the procedure and ensure good long-
term results.Study Limitations
This is a large case series with short follow-up. Although
we have shown feasibility and good short-term results by
using a single device, larger studies and/or trials and long-
term data are needed to understand efficacy of this treatment
modality.gery c December 2012
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VIV is a useful alternative in selected patients who are at
high risk for undergoing an open surgical procedure. Case
selection is of paramount importance and should be dis-
cussed during an MDT. Patients with small bioprosthetic
valves may be treated with VIV if the risk of conventional
surgery is prohibitive. It is important to be familiar with
the details of the in situ bioprostheses, including type,
size, fluoroscopic appearance, and method of implantation,
to have a successful outcome. Early results reveal improve-
ment in hemodynamics and amelioration of symptoms, but
longer follow-up with more patients is needed.A
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DrMathew R. Williams (New York, NY). I would like to thank
the American Association for Thoracic Surgery for the honor of
discussing this paper and thank you, Dr Bapat, for sending the pa-
per to me ahead of time. I had the pleasure of discussing a some-
what similar paper last year at this meeting, looking at VIV, and it
is nice as a U.S. physician to now be discussing it with actually
having experience with this procedure now that we have an ap-
proved system.
I will say that doing a transcatheter VIV is actually one of my
favorite procedures and I think it is really remarkable how well
these patients do. With this procedure in particular, it gives us
the advantages of the transcatheter procedure, a less invasive pro-
cedure with better recovery, but I think we also avoid some of the
bad things that have been affiliated with transcatheter valves—
namely, the paravalvular leak rate should probably be almost noth-
ing in most cases, and in theory we might have a lower stroke rate,
but we certainly don’t know that.
I am very impressed with your experience. It is still based on 23
patients, so I certainly don’t have anything to be critical of your
presentation, but would rather ask you some questions related to
how you conduct your clinical practice.
The first question is, I am wondering whether, given that this is
such a great procedure for a degenerated bioprosthesis, have you
changed your clinical practice in patients who are having surgical
aortic valve replacements? Namely, are you putting tissue valves in
younger patients? And if so, given what you discussed with the
gradients, are you perhaps more aggressive about a root enlarge-
ment in somebody who you wouldn’t normally if you might be op-
erating on an 80-year-old who you don’t expect to be operating on
again?
The second question is about the approach. I amwondering why
you did so many of these TA. I do understand that in some of thediovascular Surgery c Volume 144, Number 6 1379
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TA for better control, but I will be honest, I haven’t really under-
stood that, and our approach has been just to do the procedures. If
they have good access, we will do a TF; if they don’t, we will cer-
tainly do a TA.
And then the final question, which you alluded to a little bit, in
the largest experience that was presented at the Transcatheter
Valve Therapy meeting this year, there was a surprisingly high in-
cidence, or a higher incidence than I expected—it’s still a low in-
cidence—of coronary occlusion, which was most prominent with
stentless valves and, in particular, actually, the Mitroflow valve,
and I think 3 of your patients had the Mitroflow valve. I am won-
dering if you could comment on how you are addressing that po-
tential fatal complication.
Dr Bapat. Thank you, Dr Williams, for your questions. My
practice hasn’t changed, but patients are well informed now that
we are doing a VIV procedure, and patients come to us saying
they want a bioprosthetic valve because there is a good chance
that in 10 to 15 years they will have a keyhole treatment by which
we will take care of it. I give the choice to the patients regarding
what kind of valve they are going to have, depending on their life-
style and aversion to warfarin.
Yes, if I do a bioprosthetic valve in younger patients, my aim is
to put a larger bioprosthesis. Having performed TAVI as well as an
open aortic valve practice, that is going to be very important, be-
cause these patients are going to present at an age of maybe 75
or 80, and if I can at least put a 26 size Sapien valve, or whichever
device is available at that time, it will definitely add 10 more years
in each patient.
Your second question: Why TA? Absolutely. It was initially
thought that it gives you better tactile feel, better control while
you are inflating it slowly. Also if you remember with the Retro-
Flex 1 system, which lacked a nosecone crossing the valve, there
were some catastrophic events such as leaflet tears, or sometimes
the valve got stuck on the stent. And I think that is the only reason
why units like ours have gone ahead and have just done TA. But we
are changing with the availability of the NovaFlex system. And I
completely agree with you that it should be taken the same way
we treat the native aortic valve; the access should be determined
by that.
And your last question about coronary obstruction, we are very
cautious, and, as I mentioned in my presentation, with designs like
Mitroflow, designs like Trifecta, but I think all the designs, espe-
cially in small valves, these patients tend to have small sinuses
of Valsalva, and then we can do a BAV to check if there is1380 The Journal of Thoracic and Cardiovascular Sura coronary obstruction. If I am correct, there are only 3 cases re-
ported in the literature currently—2 with Mitroflow and 1 with
Mosaic—that have led to coronary obstruction. However, I think
in real life probably the incidence is much higher than that.
Dr Jahanzaib Idrees (Cleveland, Ohio). I have 1 question re-
garding younger patients in whom it would be more reasonable
to place a mechanical valve. There are patients who are hesitant
to get a mechanical valve and they don’t want to take Coumadin.
So I am interested in knowing your perspective.Would you be con-
fident in placing a bioprosthetic valve in that patient based on what
you explained your results with so that maybe later on, if the valve
wears off, you can do a VIV procedure? What would be your ap-
proach to convince that patient? Will you tell him to get a mechan-
ical valve or would you tell him that a bioprosthetic valve may still
be an option given the feasibility of a VIV procedure?What would
be your approach in that regard?
Dr Bapat. As I said before, the approach hasn’t changed, be-
cause this should still be the result for high-risk patients. We
don’t know how long these valves are going to last. As I showed
you before, circularity is very important, and in TAVI procedures
currently, you can’t control circularity in these patients. So I think
options to the patients still remain the same. If they are young, they
should decide whether they need to have a mechanical or biopros-
thetic valve. I don’t make the choice for them.
Dr Ludwig Karl von Segesser (Lausanne, Switzerland). Con-
gratulations for a nice series. You have not been very specific about
the gradients in the smaller sizes of your valves. Could you specify
about the 21 mm and the 19 mm especially?
Dr Bapat. Certainly. I think the residual gradients in all those
patients were much, much higher. So we had a drop-off average
gradient from 30 mm Hg to 9 mm Hg, but in these patients we
had residual gradients, so mean gradients of at least 20 mm Hg.
However, we undertook them as the last option, and the patients
had very good symptomatic relief.
Dr Adrian Jeremy Levine (Stoke-on-Trent, UK). Very impres-
sive work. Do you do balloon valvuloplasty for all valves of your
late series? We started, like you, the first 1 or 2, not doing it, but
now we have gone back and we balloon valvuloplasty all of
ours. What about you?
Dr Bapat. We have gone the other way around. In fact, in our
first case we did a BAV. I think the difference is because we do
the TA. You don’t need to do a BAV. And the procedure is very
short, only one pacing episode, and, again, I think doing
a BAV—unless you are worried about coronary obstruction—I
think there is no need to do a BAV.gery c December 2012
